GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » Capex-to-Operating-Income

Enzychem Lifesciences (XKRX:183490) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Enzychem Lifesciences's Capital Expenditure for the three months ended in Mar. 2024 was ₩0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₩1,847.50 Mil.

Hence, Enzychem Lifesciences's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.00.


Enzychem Lifesciences Capex-to-Operating-Income Historical Data

The historical data trend for Enzychem Lifesciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences Capex-to-Operating-Income Chart

Enzychem Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enzychem Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enzychem Lifesciences's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Enzychem Lifesciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzychem Lifesciences's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzychem Lifesciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Enzychem Lifesciences's Capex-to-Operating-Income falls into.



Enzychem Lifesciences Capex-to-Operating-Income Calculation

Enzychem Lifesciences's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-2302.361) / -14356.145
=N/A

Enzychem Lifesciences's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 1847.504
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzychem Lifesciences  (XKRX:183490) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Enzychem Lifesciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Enzychem Lifesciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzychem Lifesciences (XKRX:183490) Business Description

Traded in Other Exchanges
N/A
Address
27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences (XKRX:183490) Headlines

No Headlines